BioXcel TherapeuticsBTAI
BTAI
About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Employees: 37
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
325% more call options, than puts
Call options by funds: $17K | Put options by funds: $4K
5.76% less ownership
Funds ownership: 17.28% [Q4 2024] → 11.52% (-5.76%) [Q1 2025]
38% less funds holding
Funds holding: 48 [Q4 2024] → 30 (-18) [Q1 2025]
76% less capital invested
Capital invested by funds: $3.21M [Q4 2024] → $770K (-$2.44M) [Q1 2025]
78% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 23
96% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 24
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
306%
upside
Avg. target
$8
306%
upside
High target
$8
306%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 306%upside $8 | Buy Maintained | 23 Jun 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced the second positive recommendation by an independent Data Safety Monitoring Board (DSMB) to continue, without modification, the SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia.
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia continue without modification.
Neutral
GlobeNewsWire
1 month ago
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel granted the Company's request to continue its listing on The Nasdaq Stock Market.
Negative
Zacks Investment Research
1 month ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $2.72. This compares to loss of $13.92 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI ® in the at-home setting NEW HAVEN, Conn., May 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the first quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia is fully enrolled.
Negative
Zacks Investment Research
3 months ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $3.57 per share versus the Zacks Consensus Estimate of a loss of $4.36. This compares to loss of $12.16 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI ® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2024.
Positive
Zacks Investment Research
3 months ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Neutral
GlobeNewsWire
4 months ago
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI ® in the home setting
Neutral
GlobeNewsWire
4 months ago
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Data to support potential sNDA submission for label expansion of IGALMI ® in the home setting
Charts implemented using Lightweight Charts™